Clinical characteristics of patients from Quebec, Canada, with Morquio A syndrome: a longitudinal observational study.

Publisher: BioMed Central Country of Publication: England NLM ID: 101266602 Publication Model: Electronic Cited Medium: Internet ISSN: 1750-1172 (Electronic) Linking ISSN: 17501172 NLM ISO Abbreviation: Orphanet J Rare Dis Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2006-

Activities of Daily Living* ; Mucopolysaccharidosis IV*/drug therapy ; Mucopolysaccharidosis IV*/genetics; Canada ; Humans ; Quebec ; Retrospective Studies

Background: Morquio A syndrome is a rare, autosomal recessive, progressively debilitating disorder, with multi-system impairments and high medical burden. Quebec, Canada has a large Morquio A population, which is considered unique due to the presence of founder pathogenic variants. The objectives of this study were to document the genetic and clinical heterogeneity of patients with Morquio A in Quebec, to better characterize the phenotype of those with the French Canadian founder pathogenic variant (NM_000512.5: c.1171A>G, p.Met391Val), and to describe the natural history of the patients treated with elosulfase alfa enzyme replacement therapy. Patients with Morquio A were genotyped for pathogenic variants in the lysosomal enzyme N-acetylgalactosamine-6-sulfatase. Clinical data were retrospectively collected from medical charts of patients and included medical history, height, physical examination, respiratory function tests, electrocardiogram, echocardiogram, endurance in the 6-min walk test (6MWT), and activities of daily living (ADL) as assessed by the Mucopolysaccharidosis Health Assessment Questionnaire (MPS-HAQ). Longitudinal data were collected retrospectively and prospectively for patients treated with elosulfase alfa.
Results: A total of 33 patients, aged 5-63 years, were included in the analysis. Patients with the founder pathogenic variant (n = 17) generally exhibited a non-classical form of Morquio A. As compared with patients with a non-founder pathogenic variant (n = 16), these patients were generally taller, had greater endurance and were better able to perform ADL. However, they still had significant musculoskeletal disease. Most of the 26 patients treated with elosulfase alfa, regardless of pathogenic variant, showed improvements in endurance and ADL. After 5 to 12 months of treatment, the mean improvement from baseline in the 6MWT was 23% and 10 of 14 patients improved in at least one MPS-HAQ domain. Endurance and ADL generally continued to improve or maintained stable in the long term (up to 7 years). Four out of 19 treated patients with echocardiogram data at follow-up showed progression of cardiac disease.
Conclusions: In Quebec, Canada, Morquio A frequently manifests as a non-classical form of the syndrome due to a founder effect. Patients treated with elosulfase alfa generally show long-term improvement or stability in endurance and function, regardless of pathogenic variant.

Mol Genet Metab. 2018 Feb;123(2):127-134. (PMID: 29248359)
J Appl Genet. 2019 May;60(2):163-174. (PMID: 30927141)
Am J Med Genet A. 2015 Jan;167A(1):11-25. (PMID: 25346323)
Mol Genet Metab. 2018 Apr;123(4):479-487. (PMID: 29526614)
Orphanet J Rare Dis. 2017 Apr 26;12(1):78. (PMID: 28441951)
Union Med Can. 1973 Mar;102(3):602-7. (PMID: 4268299)
Mol Genet Metab. 2016 Sep;119(1-2):131-43. (PMID: 27380995)
CMAJ. 2017 Oct 16;189(41):E1274-E1275. (PMID: 29038319)
Orphanet J Rare Dis. 2014 Mar 07;9:32. (PMID: 24602160)
JIMD Rep. 2015;15:59-66. (PMID: 24718838)
Arch Dis Child. 2008 Jun;93(6):464-8. (PMID: 17675356)
Orphanet J Rare Dis. 2017 May 23;12(1):98. (PMID: 28535791)
Hum Mutat. 2005 Dec;26(6):500-12. (PMID: 16287098)
Eur Respir J. 2011 Jan;37(1):150-6. (PMID: 20525717)
Am J Med Genet A. 2015 Oct;167A(10):2272-81. (PMID: 26069231)
Orphanet J Rare Dis. 2014 Nov 18;9:173. (PMID: 25404155)
Orphanet J Rare Dis. 2019 Jun 13;14(1):137. (PMID: 31196221)
Mol Genet Metab. 2013 May;109(1):54-61. (PMID: 23452954)
Pediatr Endocrinol Rev. 2014 Sep;12 Suppl 1:141-51. (PMID: 25345096)
J Inherit Metab Dis. 2014 Nov;37(6):979-90. (PMID: 24810369)
Mol Genet Metab. 2015 Feb;114(2):186-94. (PMID: 25582974)
Am J Med Genet A. 2008 May 15;146A(10):1286-95. (PMID: 18412124)
PLoS Genet. 2013;9(9):e1003815. (PMID: 24086152)
Mol Genet Metab. 2017 Jul;121(3):227-240. (PMID: 28595941)
Bull World Health Organ. 2007 Nov;85(11):867-72. (PMID: 18038077)
Am J Respir Crit Care Med. 2007 Jul 15;176(2):174-80. (PMID: 17463419)

Keywords: Activities of daily living; Canada; Founder effects; Genetic disorders; Mucopolysaccharidosis IVA; Walk test

Date Created: 20200930 Date Completed: 20210618 Latest Revision: 20210618

20250114

PMC7526408

10.1186/s13023-020-01545-y

32993725